Arcturus Therapeutics Holdings (ARCT) Invested Capital (2018 - 2025)
Arcturus Therapeutics Holdings (ARCT) has disclosed Invested Capital for 8 consecutive years, with $214.0 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Invested Capital fell 11.2% year-over-year to $214.0 million, compared with a TTM value of $214.0 million through Dec 2025, down 11.2%, and an annual FY2025 reading of $214.0 million, down 11.2% over the prior year.
- Invested Capital was $214.0 million for Q4 2025 at Arcturus Therapeutics Holdings, down from $224.6 million in the prior quarter.
- Across five years, Invested Capital topped out at $352.6 million in Q1 2021 and bottomed at $173.4 million in Q3 2022.
- Average Invested Capital over 5 years is $260.9 million, with a median of $262.9 million recorded in 2024.
- The sharpest move saw Invested Capital surged 1976.36% in 2021, then crashed 40.72% in 2022.
- Year by year, Invested Capital stood at $276.1 million in 2021, then grew by 16.15% to $320.7 million in 2022, then decreased by 13.16% to $278.5 million in 2023, then decreased by 13.48% to $241.0 million in 2024, then decreased by 11.2% to $214.0 million in 2025.
- Business Quant data shows Invested Capital for ARCT at $214.0 million in Q4 2025, $224.6 million in Q3 2025, and $231.1 million in Q2 2025.